Phase 2b data from EASD 2026 show the amylin-incretin combination also cut HbA1C by up to 2.9% in adults with obesity or overweight and type 2 diabetes.
|Articles|June 13, 2022
Daily Medication Pearl: Saxagliptin/Metformin (Kombiglyze)
Author(s)Saro Arakelians, PharmD
Kombiglyze is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Advertisement
Medication Pearl of the Day: Saxagliptin/Metformin (Kombiglyze)
Indication: Kombiglyze is a combination of saxagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin, a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both saxagliptin and metformin is appropriate.
Insight:
- Dosing: 2.5/1000 to 5/1000 mg, depending on the patient and the kidney function.
- Dosage forms: 5 mg saxagliptin/500 mg metformin HCl extended-release; 5 mg saxagliptin/1000 mg metformin HCl extended-release; 2.5 mg saxagliptin/1000 mg metformin HCl extended-release.
- Adverse events:Adverse reactions reported in >5% of patients treated with metformin extended release and more commonly than in patients treated with placebo are diarrhea and nausea/vomiting.
- Mechanism of action: Increased concentrations of the incretin hormones such as glucagon-like peptide-1 and glucosedependent insulinotropic polypeptide are released into the bloodstream from the small intestine in response to meals.Metformin improves glucose tolerance in patients with type 2 diabetes, lowering both basal and postprandial plasma glucose.
Source:
Advertisement
Related to this article
Indirect comparison links orforglipron 17.2 mg to 1.5% more weight loss and 0.3% more A1C lowering than oral semaglutide 25 mg in adults with type 2 diabetes.
Phase 3 TRIUMPH-2 data presented at EASD show HbA1C reductions up to 1.6%, with GI effects, hypotension, and dysesthesia as key counseling points.
As Pharmacy Technician Day approaches, the CEO of the Pharmacy Technician Certification Board argues that real recognition means career ladders, consistent scope regulations, and investment in certification.
Tor Härnqvist, MD, discusses immune testing after invasive pneumococcal disease, serotype-informed vaccine selection, and pharmacists' role in supporting patients on immunoglobulin therapy.
In adults with type 2 diabetes at high cardiovascular (CV) risk, the oral GLP-1 RA also improved HbA1C and weight, with less hypoglycemia but more GI events.
A behavioral walking program matched supervised aerobic training for improving asthma control in a randomized trial of physically inactive adults.
American Pharmacists Month kicked off on October 1, honoring more than 700,000 pharmacy professionals and 250 years of caring for America's communities.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Butter, Beef Tallow, and LDL: Where Dietary Guidelines Diverge
2
Pharmacists Key to Lp(a) Counseling and Lipid Optimization
3
Precision in Practice: Biomarker Testing and Treatment Selection in Primary Advanced or Recurrent Endometrial Cancer
4
Why Patients Fear Statins Will Affect Their Memory
5